Beam Therapeutics Q1 2024 Earnings Report

Beam Therapeutics EPS Results

• Actual EPS: -$1.21
• Consensus EPS: -$1.42
• Beat/Miss: Beat by +$0.21
• One Year Ago EPS: -$1.33

Beam Therapeutics Revenue Results

• Actual Revenue: $7.40 million
• Expected Revenue: $17.09 million
• Beat/Miss: Missed by -$9.69 million
• YoY Revenue Growth: -69.40%

Beam Therapeutics Announcement Details

• Quarter: Q1 2024
• Date: 5/7/2024
• Time: Before Market Opens
• Conference Call Date: Tuesday, May 7, 2024
• Conference Call Time: 7:00AM ET

Beam Therapeutics (NASDAQ:BEAM), Inc. (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R. Liu, Ph.D., and a team of genome-editing pioneers. Unlike traditional CRISPR/Cas9 approaches that create double-strand DNA breaks, Beam’s base editing platform converts one DNA letter into another through targeted enzymatic reactions, minimizing genomic disruption. The company’s pipeline includes ex vivo programs for monogenic blood disorders such as sickle cell disease and beta thalassemia, as well as in vivo candidates aimed at rare metabolic and genetic conditions. Strategic collaborations with major pharmaceutical partners support the translation of these programs into clinical development.

Since its initial public offering in early 2020, Beam Therapeutics has expanded its capabilities in research, development and manufacturing, forging partnerships to scale delivery and production of its novel editors. The company’s leadership team brings together seasoned executives and scientists with expertise in protein engineering, lipid nanoparticle delivery and regulatory strategy, all united by a commitment to advance next-generation precision therapies. As Beam progresses key programs toward clinical milestones, it remains focused on translating base editing innovations into safe and effective treatments for patients worldwide.